Use of maralixibat in severe and recurrent intrahepatic cholestasis of pregnancy with concurrent benign recurrent intrahepatic cholestasis (BRIC) [0.03%]
用于严重复发性妊娠期肝内胆汁淤积症并伴有良性复发性肝内胆汁淤积症的Maralixibat的应用
Nina Rodriguez,Cecilia Katzenstein,Susanna O&#x;Kula;Mount Sinai MFM ICP Care Group;Tatyana Kushner
Nina Rodriguez
Dysphagia associated with portal hypertension and hepatocellular carcinoma, singular coincidence or hidden pathway? [0.03%]
门脉高压和肝细胞癌相关的吞咽困难：偶然事件还是隐匿通路？
Tristan Goncalves,Léa Letrillart,Claire Carlier et al.
Tristan Goncalves et al.
From the Editor's Desk… [0.03%]
编者来信
Philip Newsome,Frank Tacke,Heiner Wedemeyer et al.
Philip Newsome et al.
Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification [0.03%]
磷脂醇检测隐性饮酒及改善脂肪性肝病亚型划分的临床效用
Federica Tavaglione,Luis Antonio Díaz,Veeral Ajmera et al.
Federica Tavaglione et al.
Background & aims: The 2023 subclassification of steatotic liver disease (SLD) relies on self-reported alcohol use, which lacks diagnostic precision in routine clinical practice. Phosphatidylethanol (PEth) is a quantitati...
Reply to Diabetes-Driven Remodeling of Mesenteric Adipose Tissue: Insights into Macrophage Infiltration and Adipokine Dyshomeostasis [0.03%]
关于糖尿病驱动的肠系膜脂肪组织重塑：巨噬细胞浸润和脂因子失衡的新见解回复
Alexander Agnes Dumarey,Markus Boesch,Olivier Govaere et al.
Alexander Agnes Dumarey et al.
Rajesh K Dutta,Jude Oben,Anna Mae Diehl
Rajesh K Dutta
Attenuation of the second peak of bimodal recurrence of HBV-related HCC after curative treatment in the antiviral era [0.03%]
抗病毒时代HBV相关肝癌治愈治疗后双向复发第二高峰减缓
Landon L Chan,Anthony W H Chan,Terry C F Yip et al.
Landon L Chan et al.
Background: Recurrence in patients with hepatocellular carcinoma (HCC) treated with curative surgery or ablation follows a bimodal pattern, with early recurrence peaking at 6 months to 1 year, and late recurrence peaking ...
Steatotic liver disease induces YAP/TAZ-driven cell competition that can suppress tumor initiation [0.03%]
脂肪变性肝病诱导YAP/TAZ驱动的细胞竞争以抑制肿瘤发生
Ana Algueró-Nadal,Hasse Mol,Elena Zoppolato et al.
Ana Algueró-Nadal et al.
Background & aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are leading risk factors for liver cancer. While infla...